Bipolar disorder

New England Journal of Medicine

Volumn 351, Issue 5, 2004, Pages 476-486+518

  Belmaker, R H ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; DIURETIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; FELBAMATE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; ZONISAMIDE; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE; TRANQUILIZER;

AGRANULOCYTOSIS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; EXTRAPYRAMIDAL SYMPTOM; GENE IDENTIFICATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; KIDNEY FAILURE; LIVER TOXICITY; MANIA; PATHOGENESIS; POLYURIA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TOXICITY; WEIGHT GAIN; FEMALE; GENETICS; MALE; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; VALPROIC ACID;

EID: 3342900250     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra035354     Document Type: Review

References (91)

1. Clinical description. In. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990:15-55.
2. Beers C. A mind that found itself. Garden City, N.Y.: Doubleday, 1953.
3. Kraepelin E. Manic-depressive insanity and paranoia. Chicago: University of Chicago Press, 2002.
4. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
5. Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disord 2000;2:3-7.
6. Merikangas K, Yu K. Genetic epidemiology of bipolar disorder. Clin Neurosci Res 2002;2:127-41.
7. Akiskal HS. Classification, diagnosis and boundaries of bipolar disorders: a review. In: Maj M, Akiskal HS, López-Ibor JJ, Sartorius N, eds. Bipolar disorder. Chichester, England. John Wiley, 2002:1-95.
8. Calabrese JR, Shelton M, Rapport E, et al. A 20-month, double-blind, maintenance study of lithium versus divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling. Eur Neuropsychopharmacol 2003;13:Suppl 4:S227. abstract.
9. Coryell W, Solomon D, Turvey C, et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003;60: 914-20.
10. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-95.
11. Jamison K. Touched by fire: manic-depressive illness and the artistic temperament. New York: Free Press, 1994.
12. Schou M. Artistic productivity and lithium prophylaxis in manic-depressive illness. Br J Psychiatry 1979;135:97-103.
13. Plomin R, DeFries JC, McClearn GE, Rutter M. Behavioral genetics. 3rd ed. New York: W.H. Freeman, 1997.
14. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002;7:405-11.
15. Lenox RH, Gould TD, Manji HK. Endophenotypes in bipolar disorder. Am J Med Genet 2002;114:391-406. [Erratum, Am J Med Genet 2002;114:592.]
16. Lenox RH, Gould TD, Manji HK. Endophenotypes in bipolar disorder. Am J Med Genet 2002;114:391-406. [Erratum, Am J Med Genet 2002;114:592.]
17. Jones I, Scourfield J, McCandless F, Craddock N. Attitudes towards future testing for bipolar disorder susceptibility genes: a preliminary investigation. J Affect Disord 2002; 71:189-93.
18. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998; 97:387-97.
19. Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165: 827-9.
20. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
21. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62: 273-81.
22. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-25. [Erratum, J Clin Psychiatry 2002;63:79.]
23. Vieta E, Goikolea JM, Corbella B, et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-25. [Erratum, J Clin Psychiatry 2002;63:79.]
24. Keck PE Jr, Ice K, Ziprasidone Mania Study Group. A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania. Eur Neuropsychopharmacol 2000;10:Suppl 3:S297. abstract.
25. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002;63:Suppl 10:5-12.
26. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 1979;36:866-9.
27. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-24. [Erratum, JAMA 1994; 271:1830.]
28. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-24. [Erratum, JAMA 1994; 271:1830.]
29. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-9.
30. Ketter TA, Post RM, Denicoff K, et al. Carbamazepine. In: Goodnick PJ, ed. Mania: clinical and research perspectives. Washington, D.C.: American Psychiatric Press, 1998: 263-300.
31. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J Clin Psychiatry 1987;48:Suppl: 29-37.
32. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992;53:47-52.
33. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry 1979;36: 327-33.
34. Lindenmayer J-P, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
35. Verdoux H, Gonzales B, Takei N, Bourgeois M. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord 1996;38:81-7.
36. Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 2002;63: Suppl 10:23-8.
37. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
38. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12.
39. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002;105: 427-30.
40. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56: 407-12.
41. Chengappa KN, Levine J, Gershon S, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2: 47-55.
42. Pies R. Have we undersold lithium for bipolar disorder? J Clin Psychopharmacol 2002;22:445-9.
43. Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993;13: 276-9.
44. Walker RG. Lithium nephrotoxicity. Kidney Int Suppl 1993;42:S93-S98.
45. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981;73:95-6.
46. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A. Effect of sodium valproate on mania: the GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980;229:1-16.
47. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002;159:1005-10.
48. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290: 1467-73.
49. Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001;10:661-71. [Erratum, Expert Opin Investig Drugs 2001;10:1205a.]
50. Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001;10:661-71. [Erratum, Expert Opin Investig Drugs 2001;10:1205a.]
51. Bowden C, Calabrese J, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60:392-400.
52. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63: 275-83.
53. Mitchell PB, Malhi GS. The expanding Pharmacopoeia for bipolar disorder. Annu Rev Med 2002;53:173-88.
54. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21.
55. Montgomery DB, European College of Neuropsychopharmacology. ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. Eur Neuropsychopharmacol 2001;11:79-88.
56. Post RM, Keck P Jr, Rush AJ. New designs for studies of the prophylaxis of bipolar disorder. J Clin Psychopharmacol 2002;22: 1-3.
57. Osher Y, Cloninger CR, Belmaker RH. TPQ in euthymic manic-depressive patients. J Psychiatr Res 1996;30:353-7.
58. Hlastala SA, Frank E, Kowalski J, et al. Stressful life events, bipolar disorder, and the "kindling model." J Abnorm Psychol 2000;109:777-86.
59. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987;144: 201-4. [Erratum, Am J Psychiatry 1987;144: 542.]
60. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987;144: 201-4. [Erratum, Am J Psychiatry 1987;144: 542.]
61. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000;48:593-604.
62. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 2000;8:126-40.
63. Belmaker RH, vanPraag HM. Mania: an evolving concept. Jamaica, N.Y.: SP Medical & Scientific Books, 1980.
64. Agam G, Everall IP, Belmaker RH. The postmortem brain in psychiatric research. Norwell, Mass.: Kluwer Academic, 2002.
65. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49:741-52.
66. Yoon IS, Li PP, Siu KP, et al. Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder. Mol Psychiatry 2001;6: 678-83.
67. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 2001;49:110-6.
68. Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000;57:1061-9. [Erratum, Arch Gen Psychiatry 2002;59:12.]
69. Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000;57:1061-9. [Erratum, Arch Gen Psychiatry 2002;59:12.]
70. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 2000;47: 475-81.
71. Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997;154:1148-50.
72. Shamir A, Ebstein RP, Nemanov L, Zohar A, Belmaker RH, Agam G. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. Mol Psychiatry 1998;3:481-2.
73. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386: 824-7.
74. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry (in press).
75. Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry (in press).
76. Pearlson GD. Structural and functional brain changes in bipolar disorder: a selective review. Schizophr Res 1999;39:133-40, 162.
77. Knapp S, Mandell AJ. Short- and long-term lithium administration: effects on the brain's serotonergic biosynthetic systems. Science 1973;180:645-7.
78. Pert A, Rosenblatt JE, Sivit C, Pert CB, Bunney WE Jr. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1978;201: 171-3.
79. Ebstein R, Belmaker R, Grunhaus L, Rimon R. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature 1976;259:411-3.
80. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982;206:587-95.
81. 2A receptor activation. In: Manji HK, Bowden CL, Belmaker R, eds. Bipolar medications: mechanisms of action. Washington, D.C.: American Psychiatric Press, 2000: 249-70.
82. Jope RS, Williams MB, Li X, et al. Modulation of neuronal signal transduction systems of lithium. In: Manji HK, Bowden CL, Belmaker R, eds. Bipolar medications: mechanisms of action. Washington, D.C.: American Psychiatric Press, 2000:179-95.
83. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999;46:929-40.
84. Avissar S, Schreiber G, Danon A, Belmaker RH. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988;331:440-2.
85. Shaldubina A, Agam G, Belmaker RH. The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:855-66.
86. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996;93: 8455-9.
87. Massot O, Rousselle JC, Fillion MP, Januel D, Plantefol M, Fillion G. 5-HT1B receptors: a novel target for lithium: possible involvement in mood disorders. Neuropsychopharmacology 1999;21:530-41.
88. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci U S A 1998;95:8363-8.
89. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000;26:13-25.
90. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72:879-82.
91. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417:292-5.